Search

Displaying results 6641 - 6650 of 10000 in total
  1. Drug

    Pirlimycin

    go.drugbank.com/drugs/DB11537
    ExperimentalVet approved

    Pirlimycin hydrochloride is an antibiotic belonging to the _lincosamide_ class. Often marketed as _Pirsue_, this drug is used to treat mastitis in cattle.

  2. Drug

    Rutin

    go.drugbank.com/drugs/DB01698
    ApprovedInvestigational

    A flavonol glycoside found in many plants, including buckwheat; tobacco; forsythia; hydrangea; viola, etc. It has been used therapeutically to decrease capillary fragility.

    Synonyms: 3-[[6-O-(6-Deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl]oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one
  3. Drug

    Amredobresib

    go.drugbank.com/drugs/DB21566
    Investigational

    Amredobresib is under investigation in clinical trial NCT02516553 (BI 894999 First in Human Dose Finding Study in Advanced Malignancies). Amredobresib has a monoisotopic molecular weight of 467.25 Da. … The usage of the INN stem '-bresib' in the name indicates that Amredobresib is a inhibitor of the bromodomain and extra-terminal motif (BET) family of bromodomain (BRD) protein, antineoplastic.

  4. Drug

    Tegtociclib

    go.drugbank.com/drugs/DB21635
    Investigational

    Tegtociclib is a small molecule drug. The usage of the INN stem '-ciclib' in the name indicates that Tegtociclib is a cyclin dependant kinase inhibitor. … Tegtociclib is under investigation in clinical trial NCT05262400 (A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid

  5. Drug

    CYC116

    go.drugbank.com/drugs/DB05198
    Investigational

    In preclinical studies, CYC116 has demonstrated antitumor activity in both solid tumors and hematological cancers. … CYC116 is a novel anticancer compound with a unique target profile involving both cell cycle and angiogenesis inhibition mechanisms.

  6. Drug

    Osanetant

    go.drugbank.com/drugs/DB04872
    Investigational

    In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant. … This follows an earlier decision to discontinue development of eplivanserin for schizophrenia.

  7. Drug

    Stannsoporfin

    go.drugbank.com/drugs/DB04912
    Investigational

    Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing

    Synonyms: Sn Mesoporphyrin
  8. Drug

    Tandutinib

    go.drugbank.com/drugs/DB05465
    Investigational

    Tyrosine kinases are enzymes involved in several cellular processes and are known to be activated in cancer cells to drive tumor growth. … MLN518 is a novel, oral, small molecule designed to inhibit type III receptor tyrosine kinases, including FLT3, (platelet-derived growth-factor receptor) PDGFR and c-KIT.

  9. Drug

    Inakalant

    go.drugbank.com/drugs/DB20424
    Investigational

    Inakalant is under investigation in clinical trial NCT00255281 (Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation). Inakalant has a monoisotopic molecular weight of 446.25 Da. … Inakalant is a small molecule drug. The usage of the INN stem '-kalant' in the name indicates that Inakalant is a potassium channel blocker.

  10. Drug

    Alteminostat

    go.drugbank.com/drugs/DB19620
    Investigational

    Alteminostat is a small molecule drug. The usage of the INN stem '-inostat' in the name indicates that Alteminostat is a histone deacetylase inhibitor. … Alteminostat has a monoisotopic molecular weight of 492.28 Da.